NCT04383145进行中（未招募）不适用
INNER-B - A Post-market Clinical Follow-up Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- JOTEC GmbH
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Mortality
研究概览
简要总结
The INNER-B post-market clinical follow-up study is undertaken to evaluate the prevention of death related to a thoracoabdominal aneurysm when treated by the E-nside TAAA Multibranch Stent Graft System.
The secondary objective is to evaluate the safety and clinical performance of the device.
详细描述
In this study patients will be observed, who receive an E-nside TAAA Multibranch Stent Graft System for the endovascular treatment of a degenerative, atherosclerotic thoracoabdominal aortic aneurysm. The E-nside TAAA Multibranch Stent Graft will be implanted at the discretion of the treating physician.
Participating physicians will be asked to provide their observations collected during routine care for patients he/she had decided to treat with the E-nside TAAA Multibranch Stent Graft System. Informed consent of the patients to allow the use of their clinical records for the purpose of this observational study will be obtained before data are being collected.
The period of data collection will be approximately 60 months from the index procedure for each patient. Source document verification will be performed on 100% of patients; data from all visits will be reviewed and verified against existing source documents. Complete DICOM image files of the CT scans will be sent to the CoreLab for independent evaluation.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is between 18 and 85 years old
- •Patient has a degenerative, atherosclerotic thoracoabdominal aortic aneurysm
- •Patient has adequate iliac/femoral access compatible with an 8.5 mm OD delivery system
- •Patient's aorta has no distinct angulation in the thoracovisceral segment of the aorta ranging from 40 mm proximal to the celiac trunk to 20 mm distal to the lowest renal artery
- •All target branch vessels are suitable for antegrade cannulation
- •Diameter of the landing zone in each branch vessel to be treated is ≥ 5 mm
- •Length of landing zone in each branch vessel to be treated is ≥ 15 mm (preferably ≥ 20 mm)
- •Patient must be available for the appropriate follow-up times for the duration of the study
- •Patient has signed the informed consent before implantation of the E-nside Stent Graft
排除标准
- •Patient has allergies to materials necessary for endovascular repair (e.g. contrast media, anticoagulants or heparin, nitinol, polyester, gold, platinum-iridium)
- •Patient has systemic infection or suspected systemic infection
- •Patient has an infectious aneurysm
- •Patient has an inflammatory aneurysm
- •Patient has a ruptured aneurysm
- •Patient has a traumatic aneurysm
- •Patient has a symptomatic aneurysm
- •Patient has an aortic dissection
- •Patient has a congenital degenerative collagen disease or connective tissue disorder
- •Diameter of ostium of branch vessel to be treated < 4 mm
- •Patient has thrombocytopenia (platelet count < 150000/µl)
- •Patient has an eGFR < 30 ml/min/1.73m2 before the enrolment
- •Patient has untreated hyperthyroidism
- •Patient has a malignancy (progressive, stable or partial remission) with less than one-year projected survival
- •Patient had a myocardial infarction or cerebrovascular accident < 3 months ago
- •Patient is planned to be treated with a chimney in the left subclavian artery
- •Patient has had a previous surgical repair of descending thoracic aorta
- •Patient will be treated or had been treated with a Nellix (Endologix) or Ovation (Endologix) or Altura (Lombard Medical) or Anaconda (Vascutek) stent graft
- •Patient is enrolled or plans to be enrolled in another clinical study
- •Patient is pregnant or breastfeeding or planning to become pregnant during the course of the study.
- •Patient has a life expectancy of less than 3 years
结局指标
主要结局
Mortality
时间窗: 30-day
Rate of all-cause mortality
次要结局
- Kinking(prior to discharge/30 days, 12, 24, 36, 60 months)
- Reintervention(30 days, 3-6, 12, 24, 36, 60 months)
- Endoleak Type Ic(12, 24, 36, 60 months)
- Primary patency(prior to discharge/30 days, 12, 24, 36, 60 months)
- Primary patency of bridging stent of the superior mesenteric artery(prior to discharge/30 days, 12, 24, 36, 60 months)
- Primary patency of bridging stent of the right renal artery(prior to discharge/30 days, 12, 24, 36, 60 months)
- Endoleak Type Ia(12, 24, 36, 60 months)
- Integrity(prior to discharge/30 days, 12, 24, 36, 60 months)
- Primary patency of bridging stent of the celiac trunk(prior to discharge/30 days, 12, 24, 36, 60 months)
- Major Adverse Events (MAE)(prior to discharge, 30 days, 3-6, 12, 24, 36, 60 months)
- Delivery time(perioperative)
- Distal intercomponent separation(prior to discharge/30 days, 12, 24, 36, 60 months)
- Primary patency of bridging stent of the left renal artery(prior to discharge/30 days, 12, 24, 36, 60 months)
- Secondary patency(prior to discharge/30 days, 12, 24, 36, 60 months)
- Secondary patency of the bridging stent of the superior mesenteric artery(prior to discharge/30 days, 12, 24, 36, 60 months)
- Stent graft removal(24 hours, prior to discharge/30 days, 12, 24, 36, 60 months)
- Mortality(3-6, 12, 24, 36, 60 months)
- Rupture(30-day, 3-6, 12, 24, 36, 60 months)
- Number of intervention(s)(perioperative)
- Endoleak Type IV(12, 24, 36, 60 months)
- Proximal intercomponent separation(prior to discharge/30 days, 12, 24, 36, 60 months)
- Infection(30-day, 12, 24, 36, 60 months)
- Stable aneurysm size(12, 24, 36, 60 months)
- Increasing (> 5 mm) aneurysm size(12, 24, 36, 60 months)
- Endoleak Type Ib(12, 24, 36, 60 months)
- Endoleak Type II(12, 24, 36, 60 months)
- Endoleak Type III(12, 24, 36, 60 months)
- Endoleak of unknown origin(12, 24, 36, 60 months)
- Secondary patency of the bridging stent of the celiac trunk(prior to discharge/30 days, 12, 24, 36, 60 months)
- Secondary patency of the bridging stent of the left renal artery(prior to discharge/30 days, 12, 24, 36, 60 months)
- Secondary patency of the bridging stent of the right renal artery(prior to discharge/30 days, 12, 24, 36, 60 months)
- Technical success(24 hours)
- Primary clinical success(12, 24, 36, 60 months)
- Decreasing (< 5 mm) aneurysm size(12, 24, 36, 60 months)
- Primary technical success(24 hours)
- Clinical success(12, 24, 36, 60 months)
- Mortality(24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
LifeVest Safety and Efficacy in Real Life Settings in FranceLeft Ventricular DysfunctionCardiac EventCardiac ArrythmiasSudden Cardiac DeathNCT03319160Zoll Medical Corporation1,164
进行中（未招募）
不适用
A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)Thoracoabdominal Aortic AneurysmNCT05954793JOTEC GmbH30
进行中（未招募）
不适用
Avenir® Cemented Hip Stem - PMCFPrimary OsteoarthritisPost-Traumatic Osteoarthritis of HipFemoral Neck FracturesFemoral Head NecrosisSequelae From Previous Hip SurgeryOsteotomiesCongenital Hip DysplasiaNCT03396224Zimmer Biomet100
已完成
不适用
A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense StrongJawline Contour DeficitNCT06562075Bohus Biotech AB114
已完成
不适用
Exceed ABT Acetabular Cup Cementless SystemCorrection of Functional DeformityRheumatoid ArthritisOsteoarthritisNCT04255394Zimmer Biomet677